Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification

TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES / L. Bisbal Lopez ; tutor: A. Dal Corso, C. Gennari ; coordinatore: D. Passarella. Università degli Studi di Milano, 2023 Dec 01. 35. ciclo, Anno Accademico 2022.

TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES

L. BISBAL LOPEZ
2023

Abstract

Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification
1-dic-2023
Settore CHIM/08 - Chimica Farmaceutica
Immune-Stimulating Antibody Conjugates; Toll-Like Receptors; Resiquimod; Antibody Engineering; Prodrugs; Self-Immolative Spacers
DAL CORSO, ALBERTO
PASSARELLA, DANIELE
Doctoral Thesis
TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES / L. Bisbal Lopez ; tutor: A. Dal Corso, C. Gennari ; coordinatore: D. Passarella. Università degli Studi di Milano, 2023 Dec 01. 35. ciclo, Anno Accademico 2022.
File in questo prodotto:
File Dimensione Formato  
phd_unimi_R12797.pdf

Open Access dal 29/05/2024

Descrizione: PhD Thesis Lydia Bisbal Lopez
Tipologia: Publisher's version/PDF
Dimensione 22.07 MB
Formato Adobe PDF
22.07 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1019088
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact